AnaptysBio Historical Cash Flow

ANAB Stock  USD 25.12  0.13  0.51%   
Analysis of AnaptysBio cash flow over time is an excellent tool to project AnaptysBio future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 34.9 M or Begin Period Cash Flow of 131.8 M as it is a great indicator of AnaptysBio ability to facilitate future growth, repay debt on time or pay out dividends.
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining AnaptysBio latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AnaptysBio is a good buy for the upcoming year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.

About AnaptysBio Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in AnaptysBio balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which AnaptysBio's non-liquid assets can be easily converted into cash.

AnaptysBio Cash Flow Chart

At present, AnaptysBio's Change To Inventory is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation is expected to grow to about 34.9 M, whereas Change In Cash is projected to grow to (33.6 M).

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Change In Working Capital

The difference in the amount of working capital from one period to the next, indicating the change in a company's short-term assets and liabilities.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by AnaptysBio to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of AnaptysBio operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.
Most accounts from AnaptysBio's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into AnaptysBio current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.At present, AnaptysBio's Change To Inventory is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation is expected to grow to about 34.9 M, whereas Change In Cash is projected to grow to (33.6 M).
 2021 2022 2023 2024 (projected)
Other Non Cash Items1.5M18.6M7.6M7.9M
Depreciation2.1M2.3M2.4M2.5M

AnaptysBio cash flow statement Correlations

-0.070.16-0.14-0.150.130.270.150.11-0.32-0.120.04-0.760.210.36-0.220.030.12-0.12-0.110.25-0.25
-0.07-0.340.25-0.32-0.52-0.32-0.830.360.080.360.520.090.48-0.030.23-0.5-0.380.090.76-0.340.09
0.16-0.34-0.950.130.610.90.740.56-0.81-0.970.2-0.250.49-0.5-0.280.880.08-0.74-0.770.99-0.83
-0.140.25-0.95-0.22-0.46-0.81-0.62-0.60.770.99-0.140.18-0.550.550.28-0.76-0.190.740.72-0.930.75
-0.15-0.320.13-0.220.12-0.050.230.060.04-0.31-0.20.18-0.1-0.530.28-0.020.690.04-0.210.15-0.12
0.13-0.520.61-0.460.120.640.790.42-0.13-0.540.46-0.090.01-0.38-0.140.51-0.14-0.04-0.410.63-0.68
0.27-0.320.9-0.81-0.050.640.770.46-0.73-0.830.24-0.440.31-0.25-0.340.790.1-0.66-0.680.89-0.75
0.15-0.830.74-0.620.230.790.770.1-0.43-0.72-0.11-0.23-0.14-0.21-0.30.770.25-0.38-0.860.74-0.53
0.110.360.56-0.60.060.420.460.1-0.39-0.560.770.130.59-0.68-0.120.18-0.24-0.20.030.54-0.64
-0.320.08-0.810.770.04-0.13-0.73-0.43-0.390.750.030.41-0.570.170.37-0.76-0.120.870.67-0.790.56
-0.120.36-0.970.99-0.31-0.54-0.83-0.72-0.560.75-0.110.18-0.460.570.26-0.79-0.240.70.77-0.950.77
0.040.520.2-0.14-0.20.460.24-0.110.770.03-0.110.040.46-0.40.12-0.07-0.550.170.430.22-0.55
-0.760.09-0.250.180.18-0.09-0.44-0.230.130.410.180.04-0.31-0.470.02-0.29-0.140.320.26-0.350.4
0.210.480.49-0.55-0.10.010.31-0.140.59-0.57-0.460.46-0.31-0.33-0.030.31-0.23-0.51-0.020.52-0.65
0.36-0.03-0.50.55-0.53-0.38-0.25-0.21-0.680.170.57-0.4-0.47-0.33-0.19-0.26-0.150.160.14-0.470.51
-0.220.23-0.280.280.28-0.14-0.34-0.3-0.120.370.260.120.02-0.03-0.19-0.19-0.010.290.34-0.19-0.1
0.03-0.50.88-0.76-0.020.510.790.770.18-0.76-0.79-0.07-0.290.31-0.26-0.190.01-0.74-0.870.88-0.67
0.12-0.380.08-0.190.69-0.140.10.25-0.24-0.12-0.24-0.55-0.14-0.23-0.15-0.010.01-0.17-0.350.080.11
-0.120.09-0.740.740.04-0.04-0.66-0.38-0.20.870.70.170.32-0.510.160.29-0.74-0.170.67-0.710.45
-0.110.76-0.770.72-0.21-0.41-0.68-0.860.030.670.770.430.26-0.020.140.34-0.87-0.350.67-0.750.41
0.25-0.340.99-0.930.150.630.890.740.54-0.79-0.950.22-0.350.52-0.47-0.190.880.08-0.71-0.75-0.88
-0.250.09-0.830.75-0.12-0.68-0.75-0.53-0.640.560.77-0.550.4-0.650.51-0.1-0.670.110.450.41-0.88
Click cells to compare fundamentals

AnaptysBio Account Relationship Matchups

AnaptysBio cash flow statement Accounts

201920202021202220232024 (projected)
Change In Cash57.4M79.4M245.2M(424.4M)(35.3M)(33.6M)
Stock Based Compensation12.4M11.5M15.3M27.4M33.2M34.9M
Free Cash Flow(70.3M)(14.7M)(47.3M)(74.0M)(121.6M)(115.5M)
Change In Working Capital16.9M(6.8M)(7.5M)6.8M(324K)(307.8K)
Begin Period Cash Flow113.7M171.1M250.5M495.7M71.3M131.8M
Other Cashflows From Financing Activities(4.5M)94.5M249.7M32.2M(43K)(40.9K)
Depreciation514K559K2.1M2.3M2.4M2.5M
Other Non Cash Items676K487K1.5M18.6M7.6M7.9M
Capital Expenditures805K569K1.4M358K807K572.8K
Total Cash From Operating Activities(69.5M)(14.2M)(45.9M)(73.6M)(120.8M)(114.8M)
Change To Account Receivables1.2M(876K)174K(543K)(5.4M)(5.2M)
Net Income(97.3M)(19.9M)(57.8M)(128.7M)(163.6M)(155.4M)
Total Cash From Financing Activities(4.5M)(879K)252.3M44.0M(59.3M)(56.3M)
End Period Cash Flow171.1M250.5M495.7M71.3M36.0M34.2M
Sale Purchase Of Stock3.0M496K2.6M11.8M(50M)(47.5M)
Investments132.2M95.0M40.2M(394.5M)117.1M122.9M
Total Cashflows From Investing Activities131.4M94.5M38.8M(394.8M)(355.4M)(337.6M)
Change To Operating Activities2.4M2.1M(1.9M)(2.3M)(2.7M)(2.5M)
Change To Netincome676K12.0M1.9M18.6M21.4M22.5M
Change To Liabilities14.5M(8.9M)(4.7M)9.7M8.7M9.2M
Cash And Cash Equivalents Changes57.4M79.4M245.2M(424.4M)(382.0M)(362.9M)
Cash Flows Other Operating14.8M13.6M14.1M26.2M30.1M31.6M
Issuance Of Capital Stock0.0496K2.6M11.8M5.6M5.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AnaptysBio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.
You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.05)
Revenue Per Share
2.086
Quarterly Revenue Growth
8.047
Return On Assets
(0.18)
Return On Equity
(1.62)
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.